Skip to main content
. 2022 Aug 26;42(7):1897–1911. doi: 10.1148/rg.220045

Figure 16.

Type 3 lymph node in a 45-year-old woman with no pertinent medical history in whom left axillary lymphadenopathy was incidentally noted at chest CT. One day earlier, she received the second dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in the left arm. (A) Coronal image from chest CT shows an enlarged abnormal-appearing lymph node (arrow). (B) US image of the axilla 2 days later shows a type 3 lymph node (arrow) (BI-RADS 3). Similar morphology was observed at 6-week follow-up (not shown). (C) US image from 12-week follow-up shows a persistent type 3 lymph node (arrow), which was biopsied at the patient’s request and yielded benign lymphoid tissue.

Type 3 lymph node in a 45-year-old woman with no pertinent medical history in whom left axillary lymphadenopathy was incidentally noted at chest CT. One day earlier, she received the second dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in the left arm. (A) Coronal image from chest CT shows an enlarged abnormal-appearing lymph node (arrow). (B) US image of the axilla 2 days later shows a type 3 lymph node (arrow) (BI-RADS 3). Similar morphology was observed at 6-week follow-up (not shown). (C) US image from 12-week follow-up shows a persistent type 3 lymph node (arrow), which was biopsied at the patient’s request and yielded benign lymphoid tissue.